ETHACRYNATE SODIUM FOR INJECTION USP 50 MG
ETHACRYNIC ACID (ETHACRYNATE SODIUM) : 50 MG · DIN 02469456 · STERIMAX INC
Health Canada status: DORMANT
What is ETHACRYNATE SODIUM FOR INJECTION USP?
ETHACRYNATE SODIUM FOR INJECTION USP 50 MG contains ETHACRYNIC ACID (ETHACRYNATE SODIUM) : 50 MG. It is listed in the Health Canada Drug Product Database under DIN 02469456, held by STERIMAX INC, supplied as POWDER FOR SOLUTION for INTRAVENOUS administration. Health Canada currently lists it as dormant, status dated 27-Jun-2024. Nexara Health is a licensed Canadian wholesale distributor (DEL 3-002896-A) and can source this product for hospitals, pharmacies and clinics. Availability and lead time are confirmed per order.
What is ETHACRYNATE SODIUM FOR INJECTION USP used for?
Ethacrynate Sodium for Injection USP is especially useful in patients unresponsive to the commonly used diuretics. It has been found useful in the following conditions: Congestive Heart Failure, Acute Pulmonary Edema, Renal Edema (Nephrotic syndrome), Hepatic Cirrhosis with Ascites.
Authorized indication as written in the Health Canada product monograph. For healthcare professionals and licensed purchasers; this is not medical advice.
Product details and regulatory record
| DIN | 02469456 |
|---|---|
| Brand name | ETHACRYNATE SODIUM FOR INJECTION USP |
| Generic / active ingredient | ETHACRYNIC ACID (ETHACRYNATE SODIUM) : 50 MG |
| Manufacturer | STERIMAX INC |
| Strength | 50 MG |
| Dosage form | POWDER FOR SOLUTION |
| Route of administration | INTRAVENOUS |
| Schedule | Prescription |
| ATC code | C03CC01 ETACRYNIC ACID |
| AHFS class | 40:28.08 |
| Biosimilar | No |
| Health Canada status | DORMANT |
| Status date | 27-Jun-2024 |
| Original market date | 2018-03-29 00:00:00 |
How is it stored and handled?
Store at 15 °C-30 °C.
How is it supplied?
Vials containing ethacrynate sodium equivalent to 50 mg of ethacrynic acid.
What can be used instead?
Other Canadian products sharing ATC code C03CC01 ETACRYNIC ACID. 2 of 6 DINs in this group are currently marketed — marketed products are listed first, because that is what can actually be bought. These tables describe supply, not clinical equivalence: substitution rests with the prescriber or pharmacist, and interchangeability is determined provincially.
| Product | Strength | Form | Manufacturer | Health Canada status | DIN |
|---|---|---|---|---|---|
| EDECRIN | 25 MG | TABLET | BAUSCH HEALTH, CANADA INC. | MARKETED | DIN 02258528 |
| ETHACRYNATE SODIUM | 50 MG | POWDER FOR SOLUTION | STERIMAX INC | MARKETED | DIN 02462362 |
| EDECRIN TAB 50MG | 50 MG | TABLET | MERCK FROSST CANADA & CIE, MERCK FROSST CANADA & CO. | CANCELLED POST MARKET | DIN 00016497 |
| ETHACRYNATE SODIUM FOR INJECTION | 50 MG | POWDER FOR SOLUTION | ENDO PAR INNOVATION COMPANY, LLC | CANCELLED PRE MARKET | DIN 02479591 |
| SODIUM EDECRIN | 50 MG | POWDER FOR SOLUTION | BAUSCH HEALTH, CANADA INC. | DORMANT | DIN 00268313 |
How can I get it?
Nexara Health supplies this product to licensed Canadian buyers — pharmacies, hospitals, clinics, licensed distributors, and clinical trial sponsors or their CROs. We confirm stock, pack size, expiry and pricing at the time of quotation. If the product is on backorder or in shortage, we identify equivalent alternatives and import options where permitted.
Ordering questions
Who can buy this from Nexara?
Licensed entities only. Nexara holds Health Canada establishment licence DEL 3-002896-A and ships only to a licensed address.
Is there a minimum order?
Yes, set per product line and per pack multiple rather than on the order total, so you are never asked to buy a part-pack. The minimum for this line is confirmed with your quote.
What is the lead time?
Confirmed per order at quotation, and it depends on current stock position and whether the product is in shortage.
Can Nexara supply this for a clinical trial?
Yes — comparator and background-therapy supply, including sourcing from other markets where a Canadian pack will not satisfy the protocol. Clinical trial supply.